Celltrion to unveil Zymfentra’s clinical results at US gastroenterology meet

Celltrion said it is participating in Digestive Disease Week (DDW) 2024 in Washington, D.C., from last Saturday to Tuesday to showcase positive clinical results for Zymfentra, the world's only subcutaneous (SC) formulation of infliximab and to help drive prescribing preferences among local healthcare providers.

DDW is the world's largest gathering of influential global experts in gastroenterology, hepatology, endoscopy, and digestive surgery. This year, more than 13,000 healthcare professionals worldwide are gathering to share and communicate the latest medical trends in the field of inflammatory bowel disease (IBD)

This is Celltrion's first IBD meeting in the U.S. since launching Zymfentra in March. The company has been engaged in various activities to raise product and company awareness among U.S. healthcare providers and key stakeholders.

On Sunday (local time), Celltrion announced results from the two-year (102-week) long-term follow-up of the global phase 3 Zymfentra study in 180 patients with Crohn's disease (CD) and 237 patients with ulcerative colitis (UC). The long-term results were presented for the first time in the U.S., following the presentation at the European Crohn's and Colitis Organization (ECCO) Congress, also for the first time in February, where European healthcare providers well received.

The study looked at long-term efficacy and safety in patients who received 54 weeks (one year) of maintenance therapy with Zymfentra and extended treatment to Week 102. Results showed similar efficacy results at week 102 to week 54, and no new safety concerns were identified. The positive efficacy and safety findings are expected to ease the burden on U.S. physicians prescribing Zymfentra and raise prescribing preferences.

In addition to the data release, Celltrion plans to launch various marketing activities to promote Zymfentra to U.S. physicians attending DDW. On Tuesday, Celltrion will host a seminar titled "Achieving long-term treatment goal with ZYMFENTRA—endoscopic remission and mucosal healing" at the Celltrion booth. The seminar will provide an analysis of Zymfentra based on the latest trends in IBD treatment, the company said.

In addition, the company will host a symposium on Tuesday on "Understanding ZYMFENTRA—The first and only subcutaneous infliximab offering a new therapeutic approach in UC and CD maintenance" to actively promote Zymfentra’s therapeutic efficacy and product competitiveness to attendees. The strategy is to create a favorable environment for U.S. physicians to prescribe Zymfentra and increase their preference.

"The continued release of study data demonstrating the efficacy and safety of Zymfentra at world-renowned conferences continues to generate strong interest and response from global thought leaders," a Celltrion official said. "With the recent addition of preferred drug status on the formulary of a major U.S. Pharmacy Benefit Management (PBM), we expect Zymfentra prescribing to gain further momentum as we expand our marketing efforts. We will continue aggressively promoting product competitiveness and increasing preference among U.S. IBD physicians attending conferences to ensure that our efforts translate into substantial sales."